Tuttle; Ronald R.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Tuttle; Ronald R..The latest application filed is for "melanocortin receptor-3 ligands to treat sexual dysfunction".

Company Profile

0.19.0

Tuttle; Ronald R. - Escondido CA
Tuttle; Ronald R. - Oceanside CA
Tuttle; Ronald R. - Plantation FL

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Melanocortin receptor-3 ligands to treat sexual dysfunction Grant 6,534,503 - Dines , et al. March 18, 2	2003-03-18
HP-3228 and related peptides to treat sexual dysfunction Grant 6,284,735 - Girten , et al. September 4, 2	2001-09-04
Cytokine restraining agents Grant 6,245,738 - Suto , et al. June 12, 2	2001-06-12
Use of cytokine restraining agents to treat inflammatory bowel disease Grant 5,888,969 - Girten , et al. March 30, 1	1999-03-30
Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels Grant 5,786,332 - Girten , et al. July 28, 1	1998-07-28
Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels Grant 5,760,001 - Girten , et al. June 2, 1	1998-06-02
Use of a cytokine regulatory agent to treat rheumatoid arthritis Grant 5,741,774 - Girten , et al. April 21, 1	1998-04-21
Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels Grant 5,726,156 - Girten , et al. March 10, 1	1998-03-10
Method and compounds for aica riboside delivery and for lowering blood glucose Grant 5,658,889 - Gruber , et al. August 19, 1	1997-08-19
Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist Grant 5,460,605 - Tuttle , et al. October 24, 1	1995-10-24
Cytokine restraining agents Grant 5,420,109 - Suto , et al. May 30, 1	1995-05-30
Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist Grant 5,286,252 - Tuttle , et al. February 15, 1	1994-02-15
Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist Grant 5,234,404 - Tuttle , et al. August 10, 1	1993-08-10
Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist Grant 5,108,363 - Tuttle , et al. April 28, 1	1992-04-28
Method of treating pruritus with nalmefene and clonidine Grant 4,946,848 - Tuttle , et al. August 7, 1	1990-08-07
Glucuronic acid derivatives of opioid antagonists Grant 4,774,230 - Tuttle , et al. September 27, 1	1988-09-27
Hyperkinetic child treatment agent Grant 4,483,860 - Tuttle November 20, 1	1984-11-20
3,4-Dih ydroxy-N-[3-(4-dihydroxyphenyl)-1-methyl-n-propyl]-beta-phenethylamine cyclodextrin complexes Grant 4,425,336 - Tuttle January 10, 1	1984-01-10
3,4-Di -isobutyryloxy-N-[3-(4-isobutyryloxyphenyl)-1-methyl-n-propyl]-beta-phene thylamine cyclodextrin complexes Grant 4,424,209 - Tuttle January 3, 1	1984-01-03

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.